Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06852231 · 1 trial · 1 indication
Treatment-related AE are any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to Y days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to study drug is assessed either yes or no by the investigator. Participants with multiple occurrences of an AE within a category are counted once within the category.
Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid albumin, total protein); urinalysis (decimal logarithm of reciprocal of hydrogen ion activity \[pH\], glucose, protein, blood, ketones, microscopy\[if urine tested positive for blood or protein\]).
Following parameters were analyzed for examination of vital signs: systolic and diastolic blood pressure, pulse rate, and body temperature.
Absolute values and changes from baseline for ECG parameters
Cardiac rhythms measured by continuous cardiac monitoring
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo |
| PF-06852231 | EXPERIMENTAL | Single ascending doses of PF-06852231 |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Treatment with placebo |
| PF-06852231 | DRUG | Treatment with PF-06852231 |
Inclusion Criteria: 1. Healthy female subjects of non-childbearing potential and male subjects, who at the time of screening are between ages of 18 and 55 years inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination,...
PF-06852231 is an investigational small molecule being developed by Pfizer, Inc. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers to evaluate its safety, tolerability, and pharmacokinetics. It is not approved and remains in clinical development.
PF-06852231 is being studied for use in healthy volunteers. The completed Phase 1 trial assessed the safety, tolerability, and pharmacokinetics of single doses of the drug. Its intended therapeutic use has not been established, as it is still in early clinical development.
PF-06852231 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company conducted a Phase 1 clinical trial of the drug in healthy volunteers.
PF-06852231 is in Phase 1 clinical development. One Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities and is still undergoing clinical evaluation.
PF-06852231 has one completed clinical trial, NCT03217604, titled "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects." This Phase 1 trial enrolled 17 participants in Belgium and was placebo-controlled and double-blinded.